Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
VEYVONDI IU (Shire Australia Pty Ltd)
Product name
VEYVONDI IU
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
173 working days (175)
Active ingredients
vonicog alfa
Registration type
NCE/NBE
Indication
VEYVONDI (powder for injection with solvent vials) is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated, for the:
- treatment of haemorrhage and surgical bleeding
- prevention of surgical bleeding.
VEYVONDI should not be used in the treatment of Haemophilia A.